What's new | Periotherapia Co., Ltd.

TOP What’s new

2025.03.07
Clinical Trial Progress

Providing our developed antibody drug (P…
2025.01.31
Funding-related

In addition to the additional investment…
2024.10.03
Notices

We will be exhibiting at the Japan Healt…
2024.09.18
Media Relations

Selected for the 2024 edition of Toyo Ke…
2024.06.27
Funding-related

In addition to the Series D/D1 round of …
2024.04.30
Joint Research and Licensing

We have signed a joint research agreemen…
2023.12.01
Awards and Selections

The project was selected for the AMED ‘D…
2023.10.30
Funding-related

The company has secured a total investme…
2023.07.25
Media Relations

Our efforts have been featured in Nikkei…
2022.03.09
Funding-related

We have secured an additional investment…

2025.03.07
Clinical Trial Progress

Providing our developed antibody drug (P…
2025.01.31
Funding-related

In addition to the additional investment…
2024.10.03
Notices

We will be exhibiting at the Japan Healt…
2024.09.18
Media Relations

Selected for the 2024 edition of Toyo Ke…
2024.06.27
Funding-related

In addition to the Series D/D1 round of …
2024.04.30
Joint Research and Licensing

We have signed a joint research agreemen…
2023.12.01
Awards and Selections

The project was selected for the AMED ‘D…
2023.10.30
Funding-related

The company has secured a total investme…
2023.07.25
Media Relations

Our efforts have been featured in Nikkei…
2022.03.09
Funding-related

We have secured an additional investment…

2025.03.07
Clinical Trial Progress

Providing our developed antibody drug (P…
2025.01.31
Funding-related

In addition to the additional investment…
2024.10.03
Notices

We will be exhibiting at the Japan Healt…
2024.09.18
Media Relations

Selected for the 2024 edition of Toyo Ke…
2024.06.27
Funding-related

In addition to the Series D/D1 round of …
2024.04.30
Joint Research and Licensing

We have signed a joint research agreemen…
2023.12.01
Awards and Selections

The project was selected for the AMED ‘D…
2023.10.30
Funding-related

The company has secured a total investme…
2023.07.25
Media Relations

Our efforts have been featured in Nikkei…
2022.03.09
Funding-related

We have secured an additional investment…

2025.03.07
Clinical Trial Progress

Providing our developed antibody drug (P…
2025.01.31
Funding-related

In addition to the additional investment…
2024.10.03
Notices

We will be exhibiting at the Japan Healt…
2024.09.18
Media Relations

Selected for the 2024 edition of Toyo Ke…
2024.06.27
Funding-related

In addition to the Series D/D1 round of …
2024.04.30
Joint Research and Licensing

We have signed a joint research agreemen…
2023.12.01
Awards and Selections

The project was selected for the AMED ‘D…
2023.10.30
Funding-related

The company has secured a total investme…
2023.07.25
Media Relations

Our efforts have been featured in Nikkei…
2022.03.09
Funding-related

We have secured an additional investment…

2025.03.07
Clinical Trial Progress

Providing our developed antibody drug (P…
2025.01.31
Funding-related

In addition to the additional investment…
2024.10.03
Notices

We will be exhibiting at the Japan Healt…
2024.09.18
Media Relations

Selected for the 2024 edition of Toyo Ke…
2024.06.27
Funding-related

In addition to the Series D/D1 round of …
2024.04.30
Joint Research and Licensing

We have signed a joint research agreemen…
2023.12.01
Awards and Selections

The project was selected for the AMED ‘D…
2023.10.30
Funding-related

The company has secured a total investme…
2023.07.25
Media Relations

Our efforts have been featured in Nikkei…
2022.03.09
Funding-related

We have secured an additional investment…

2025.03.07
Clinical Trial Progress

Providing our developed antibody drug (P…
2025.01.31
Funding-related

In addition to the additional investment…
2024.10.03
Notices

We will be exhibiting at the Japan Healt…
2024.09.18
Media Relations

Selected for the 2024 edition of Toyo Ke…
2024.06.27
Funding-related

In addition to the Series D/D1 round of …
2024.04.30
Joint Research and Licensing

We have signed a joint research agreemen…
2023.12.01
Awards and Selections

The project was selected for the AMED ‘D…
2023.10.30
Funding-related

The company has secured a total investme…
2023.07.25
Media Relations

Our efforts have been featured in Nikkei…
2022.03.09
Funding-related

We have secured an additional investment…

2025.03.07
Clinical Trial Progress

Providing our developed antibody drug (P…
2025.01.31
Funding-related

In addition to the additional investment…
2024.10.03
Notices

We will be exhibiting at the Japan Healt…
2024.09.18
Media Relations

Selected for the 2024 edition of Toyo Ke…
2024.06.27
Funding-related

In addition to the Series D/D1 round of …
2024.04.30
Joint Research and Licensing

We have signed a joint research agreemen…
2023.12.01
Awards and Selections

The project was selected for the AMED ‘D…
2023.10.30
Funding-related

The company has secured a total investme…
2023.07.25
Media Relations

Our efforts have been featured in Nikkei…
2022.03.09
Funding-related

We have secured an additional investment…

News

Providing our developed antibody drug (P…

In addition to the additional investment…

We will be exhibiting at the Japan Healt…

Selected for the 2024 edition of Toyo Ke…

In addition to the Series D/D1 round of …

We have signed a joint research agreemen…

The project was selected for the AMED ‘D…

The company has secured a total investme…

Our efforts have been featured in Nikkei…

We have secured an additional investment…

Providing our developed antibody drug (P…

In addition to the additional investment…

We will be exhibiting at the Japan Healt…

Selected for the 2024 edition of Toyo Ke…

In addition to the Series D/D1 round of …

We have signed a joint research agreemen…

The project was selected for the AMED ‘D…

The company has secured a total investme…

Our efforts have been featured in Nikkei…

We have secured an additional investment…

Providing our developed antibody drug (P…

In addition to the additional investment…

We will be exhibiting at the Japan Healt…

Selected for the 2024 edition of Toyo Ke…

In addition to the Series D/D1 round of …

We have signed a joint research agreemen…

The project was selected for the AMED ‘D…

The company has secured a total investme…

Our efforts have been featured in Nikkei…

We have secured an additional investment…

Providing our developed antibody drug (P…

In addition to the additional investment…

We will be exhibiting at the Japan Healt…

Selected for the 2024 edition of Toyo Ke…

In addition to the Series D/D1 round of …

We have signed a joint research agreemen…

The project was selected for the AMED ‘D…

The company has secured a total investme…

Our efforts have been featured in Nikkei…

We have secured an additional investment…

Providing our developed antibody drug (P…

In addition to the additional investment…

We will be exhibiting at the Japan Healt…

Selected for the 2024 edition of Toyo Ke…

In addition to the Series D/D1 round of …

We have signed a joint research agreemen…

The project was selected for the AMED ‘D…

The company has secured a total investme…

Our efforts have been featured in Nikkei…

We have secured an additional investment…

Providing our developed antibody drug (P…

In addition to the additional investment…

We will be exhibiting at the Japan Healt…

Selected for the 2024 edition of Toyo Ke…

In addition to the Series D/D1 round of …

We have signed a joint research agreemen…

The project was selected for the AMED ‘D…

The company has secured a total investme…

Our efforts have been featured in Nikkei…

We have secured an additional investment…

Providing our developed antibody drug (P…

In addition to the additional investment…

We will be exhibiting at the Japan Healt…

Selected for the 2024 edition of Toyo Ke…

In addition to the Series D/D1 round of …

We have signed a joint research agreemen…

The project was selected for the AMED ‘D…

The company has secured a total investme…

Our efforts have been featured in Nikkei…

We have secured an additional investment…

Contact